Clinical trial
Phosphatidylinositol 3-kinase (PI3K) Pathway Analysis in Tumor Tissue and Circulating DNA to Obtain Further Insight in the Efficacy of Everolimus When Combined With Exemestane: A Side-study Protocol Attached to Standard Treatment With Everolimus and Exemestane for Postmenopausal Patients With Hormone Receptor-positive Advanced Metastatic Breast Cancer, Who Have Progressed on Anastrozole or Letrozole
NCT02109913 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phosphatidylinositol 3-kinase (PI3K) Pathway Analysis in Tumor Tissue and Circulating DNA to Obtain Further Insight in the Efficacy of Everolimus When Combined With Exemestane: A Side-study Protocol Attached to Standard Treatment With Everolimus and Exemestane for Postmenopausal Patients With Hormone Receptor-positive Advanced Metastatic Breast Cancer, Who Have Progressed on Anastrozole or Letrozole
- Lead sponsor
- Amsterdam UMC, location VUmc
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- March 31, 2014
- Completion date
- January 31, 2021
- Enrollment
- 175 (estimated)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.
hormone receptor positive malignant neoplasm of breast, metastatic breast cancer